For your patients with stage II/III HR+/HER2- eBC,

Start with KISQALI 400 mg—the starting dose chosen to reduce both the risk of recurrence and dose-dependent adverse reactions

• KISQALI is given as 400 mg (2 x 200-mg tablets) orally, once daily (3 weeks on, 1 week off) for 36 months with an AI¹

  • Review the full Prescribing Information for recommended dosing of selected AI 

  • An LHRH agonist should be used concomitantly with AI in men and premenopausal women

  • Patients should continue treatment for 3 years or until disease recurrence or unacceptable toxicity

  • KISQALI can be taken with or without food

  • Store refrigerated at 2°C to 8°C (36°F to 46°F). Excursions permitted between 2°C and 15°C (36°F and 59°F)

  • After dispensing, patients may store at room temperature at 20°C to 25°C (68°F to 77°F) for up to 2 months

  • Store tablets in the original blister pack

Starting dose modification for severe renal impairment¹

• The recommended starting dose is 200 mg once daily for patients with severe renal impairment